- Home
- GHI vs FDMT Comparison
GHI vs FDMT Comparison
Compare GHI & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
GHI
Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Current Price
Company Overview
Basic Information| Metric | GHI | FDMT |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 254.1M | 391.8M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | GHI | FDMT |
|---|---|---|
| Price | $6.81 | $8.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $13.00 | ★ $30.33 |
| AVG Volume (30 Days) | 173.1K | ★ 1.1M |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | ★ 21.61% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $26,247,399.00 | $120,000.00 |
| Revenue This Year | $201.02 | $21,181.08 |
| Revenue Next Year | $2.87 | $162.43 |
| P/E Ratio | $40.60 | ★ N/A |
| Revenue Growth | N/A | ★ 605.88 |
| 52 Week Low | $6.01 | $2.24 |
| 52 Week High | $13.29 | $12.34 |
Technical Indicators
Market Signals| Indicator | GHI | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 48.66 | 37.69 |
| Support Level | $6.30 | $10.56 |
| Resistance Level | $7.44 | $11.81 |
| Average True Range (ATR) | 0.30 | 0.86 |
| MACD | 0.13 | -0.26 |
| Stochastic Oscillator | 52.22 | 12.06 |
Price Performance
Historical ComparisonAbout GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.